Akero Therapeutics COO Jonathan Younger sells $280,330 in inventory

Jonathan Younger, Chief Working Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), just lately offered 10,000 shares of the corporate’s frequent inventory. The transaction comes because the inventory has proven robust momentum, gaining over 31% previously six months. In response to InvestingPro evaluation, the corporate seems barely undervalued at present ranges. The shares had been offered at a weighted-average value of $28.033, with transaction costs starting from $27.72 to $28.34. Following this transaction, Younger holds 218,083 shares instantly. The sale was performed beneath a pre-established Rule 10b5-1 buying and selling plan, adopted in June 2024. Moreover, Younger has oblique holdings of 20,000 shares every in three separate irrevocable trusts, that are managed by his partner for the good thing about their kids. Younger disclaims useful possession of those trust-held securities. InvestingPro information reveals the corporate maintains robust liquidity with a present ratio of 17.25, and its inventory usually strikes independently of broader market traits. Subscribers can entry 8 further ProTips and complete monetary metrics for deeper evaluation.

In different current information, Keros Therapeutics introduced a voluntary pause in dosing for sure arms of its Section 2 TROPOS Trial attributable to surprising instances of pericardial effusion. Nevertheless, dosing continues on the 1.5 mg/kg stage. The corporate goals to current topline information from all remedy arms of the trial within the second quarter of 2025.

In the meantime, Akero Therapeutics has been the topic of optimistic consideration from Citi, which initiated protection on the corporate with a Purchase ranking. That is based mostly on the potential of efruxifermin, a remedy for metabolic dysfunction-associated steatohepatitis (MASH), which is at present being developed by Akero.

Moreover, Akero reported optimistic outcomes from its Section 2b HARMONY research, which evaluated the efficacy of efruxifermin for treating MASH. Over 40% of members exhibited regression of liver fibrosis after 96 weeks of remedy.

The corporate has additionally made vital progress with its Section 3 SYNCHRONY Outcomes trial for MASH sufferers with compensated cirrhosis. The primary affected person has been dosed, marking a essential step for Akero because it now has all three Section 3 trials of efruxifermin underway.

Lastly, traders are eagerly anticipating the Week 96 information launch from the continued Section 2b SYMMETRY research, anticipated within the first quarter of 2025. This information will present insights into the long-term results of efruxifermin on MASH sufferers with fibrosis stage 4.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.